Such TMAs have already proven their ability to uncover stage-specific molecular alterations, for example in prostate cancer progression, where the amplification of the Androgen Receptor (AR) gene [52] or the amplification of IGFBP2 locus (insulin-like growth factor binding protein 2) [53] were usually found in hormone refractory end-stage prostate cancers but rarely observed in untreated primary tumors. The gene discussed is IGFBP2; the disease is prostate cancer.